Future Financial Wealth Managment LLC Acquires Shares of 2,200 Gilead Sciences, Inc. (NASDAQ:GILD)

Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 2,200 shares of the biopharmaceutical company’s stock, valued at approximately $184,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Manning & Napier Advisors LLC purchased a new stake in shares of Gilead Sciences during the second quarter worth $25,328,000. Legal & General Group Plc lifted its position in shares of Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Gilead Sciences during the first quarter worth $462,000. Brookstone Capital Management lifted its position in shares of Gilead Sciences by 751.1% during the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock worth $9,322,000 after acquiring an additional 112,305 shares in the last quarter. Finally, Comerica Bank lifted its position in shares of Gilead Sciences by 10.7% during the fourth quarter. Comerica Bank now owns 329,990 shares of the biopharmaceutical company’s stock worth $26,733,000 after acquiring an additional 31,849 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Up 0.9 %

Shares of NASDAQ:GILD opened at $85.21 on Wednesday. The stock’s 50-day moving average price is $79.34 and its 200-day moving average price is $72.07. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86. The stock has a market capitalization of $106.16 billion, a P/E ratio of 236.69, a price-to-earnings-growth ratio of 2.91 and a beta of 0.18. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.61%. Gilead Sciences’s payout ratio is currently 855.56%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock valued at $3,033,340 in the last quarter. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GILD shares. Robert W. Baird restated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Barclays increased their price objective on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday. Piper Sandler reiterated an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 11th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research report on Monday, July 8th. Finally, Wells Fargo & Company upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $78.00 to $100.00 in a research report on Monday. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $83.94.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.